It has also been reported that only 25% of NPC patients will benefit from anti-PD-1/PD-L1 immunotherapy, highlighting the critical need for further research into novel therapeutic regimens [25]. The gene discussed is PDCD1; the disease is nasopharyngeal carcinoma.